Norway's new principles for primary prevention of cardiovascular disease: Age differentiated risk thresholds

BMJ

Volumn 343, Issue 7815, 2011, Pages

  Norheim, Ole Frithjof ^a   Gjelsvik, Bjørn ^b   Klemsdal, Tor Ole ^c   Madsen, Steinar ^d   Meland, Eivind ^a   Narvesen, Stein ^e   Negård, Anne ^f   Njølstad, Inger ^g   Tonstad, Serena ^c   Ulvin, Frøydis ^e   Wisløff, Torbjørn ^h  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d Norwegian Medicines Agency   (Norway)

^e Norwegian Heart and Lung Patient Organization   (Norway)

^f Norwegian Directorate of Health   (Norway)

^g UNIVERSITY OF TROMSØ   (Norway)

^h NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CHOLESTEROL;

AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; DIET THERAPY; DRUG INDICATION; EUROPEAN UNION; HEALTH CARE POLICY; HEART PROTECTION; HUMAN; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MENOPAUSE; NATIONAL HEALTH ORGANIZATION; NORWAY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE;

EID: 79960296926     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d3626     Document Type: Review

References (19)

1. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardiovasc Prev Rehabil 2007;14(suppl 2):S1-113.
2. Getz L, Sigurdsson J, Hetlevik I, Kirkengen AL, Romundstad S, Holmen J. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. BMJ 2005;331:551-2.
3. Getz L, Kirkengen AL, Hetlevik I, Romundstad S, Sigurdsson JA. Ethical dilemmas arising from implementation of the European guidelines on cardiovascular disease prevention in clinical practice. A descriptive epidemiological study. Scand J Prim Health Care 2004;22:202-8. (Pubitemid 39601980)
4. Hetlevik I. The role of clinical guidelines in cardiovascular risk intervention in general practice [PhD thesis]. Norwegian University of Science and Technology, 1999.
5. Meland E, Ellekjær H, Gjelsvik B, Kimsaas A, Holmen J, Hetlevik I. Medikamentell forebyggende av hjerte- og karsykdommer i allmennpraksis. Tidsskri Nor Lægeforen 2000;120:2643-7.
6. Hartz I, Njølstad I, Eggen AE. Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001. Eur Heart J 2005;26:2673-80. (Pubitemid 41746690)
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338: b1665.
8. Norheim OF, Gjelsvik B, Kjeldsen SE, Klemsdal TO, Madsen S, Meland E, et al. Retningslinjer for individuell primærforebygging av hjerte- og karsykdommer [Norwegian]. Oslo: Helsedirektoratet, 2009.
9. Norheim OF. Healthcare rationing - are additional criteria needed for assessing evidence based clinical practice guidelines? BMJ 1999;319:1426-29.
10. Fretheim A, Håheim LL, Brørs O, Kjeldsen SE, Kristiansen IS, Madsen S, et al. Primærforebygging av hjerte- og karsykdom [Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions]. Rapport nr 20-2008. Oslo: Nasjonalt kunnskapssenter for helsetjenesten, 2008.
11. Wisløff T, Norheim OF, Halvorsen S, Selmer RM, Kristiansen IS. Kostnader og leveårsgevinster ved medikamentell primærforebygging av hjertekarsykdom [Health economic evaluation of primary prevention strategies against cardiovascular disease]. Rapport nr 21-2008. Oslo: Nasjonalt kunnskapssenter for helsetjenesten, 2008.
12. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ 2008;336:995-8. (Pubitemid 351656090)
13. Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005;365:434-41. (Pubitemid 40179232)
14. Selmer R, Lindman AS, Tverdal A, Pedersen JI, Njolstad I, Veierod DM. Modell for estimering av kardiovaskulær risiko i Norge. Tidsskr Nor Laegeforen 2008;128:286-90.
15. Lindman AS, Veierod MB, Pedersen JI, Tverdal A, Njolstad I, Selmer R. The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway. Eur J Cardiovasc Prev Rehabil 2007;14:501-7. (Pubitemid 47229729)
16. Norheim OF. Clinical priority setting. BMJ 2008;337:a1846.
17. Bonneux L. Cardiovascular risk models. Moral implications of models based on absolute risk could be better understood BMJ 2007;335:107-8.
18. Broome J. Discounting the future. Philos Public Aff 1994;23:128-56.
19. National Institute for Health and Clinical Excellence. NICE public health guidance 25: prevention of cardiovascular disease. NICE, 2010.